3D Bio Therapeutics, Inc. 3DBio Therapeutics Receives FDA Rare Pediatric Disease Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients December 6, 2019
Read More
Read news items items specific to Ponce Therapeutics or about other Rapha Capital-related entities. Also see scientific articles detailing the rapid advances in the important science of anti-aging
News
3D Bio Therapeutics, Inc. 3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients November 19, 2019
Poseida Therapeutics, Inc. Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting November 5, 2019
NexImmune Inc. NexImmune Receives IND Clearance for Phase 1/2 trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome ND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients…
Poseida Therapeutics, Inc. Poseida Therapeutics Appoints Kerry Ingalls as Chief Operating Officer October 10, 2019
Rapha Capital and ControlRad, Inc. Rapha Capital Management Participates in Series B Financing for ControlRad, Inc. Led by Questa Capital October 2, 2019